{"id":"W2898590494","doi":"10.1093/annonc/mdy287.079","title":"Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; MorphoSys; Swedish Orphan Biovitrum; Astellas Pharma; Regeneron Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Phases of clinical research; Head and neck squamous-cell carcinoma; Cancer; Surgery; Clinical trial; Head and neck cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002816402,0.0002520533,0.0007821735,0.0001685165,0.0001469844,0.00000511471,0.0002244259,0.0000612993,0.0002090935],"category_scores_gemma":[0.0001854162,0.0001422584,0.00006885541,0.0003555439,0.0004133837,0.00004609746,0.0001775583,0.0002555648,0.00002382664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001275848,"about_ca_system_score_gemma":0.0004034325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002391808,"about_ca_topic_score_gemma":0.001269235,"domain_scores_codex":[0.9979805,0.0002473189,0.0005376863,0.0003865296,0.0003899678,0.0004579731],"domain_scores_gemma":[0.998273,0.0003635028,0.0003118549,0.0005116246,0.0004371754,0.0001028327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09411696,0.05324534,0.6377034,0.0003192251,0.0005859333,0.002308299,0.02859054,0.000007053907,0.00007768571,0.00002524557,0.02015834,0.162862],"study_design_scores_gemma":[0.04691885,0.4380152,0.4936465,0.00005910727,0.0005182708,0.0001637075,0.002793705,0.00004037717,0.001338717,0.00004687316,0.01613924,0.0003194324],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925029,0.0004164433,0.000004632437,0.00127152,0.0002928368,0.001647494,0.00003200303,0.00001483099,0.003817356],"genre_scores_gemma":[0.9985419,0.00002592744,0.0001435237,0.0007158811,0.0001330574,0.0001072619,0.000009554364,0.000031142,0.0002917549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3847699,"threshold_uncertainty_score":0.5801131,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06840397306266671,"score_gpt":0.3853811545560575,"score_spread":0.3169771814933908,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}